- Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
This study compares two medicines, entrectinib and crizotinib, for advanced lung cancer (non-small cell lung cancer) that has a specific genetic change called ROS1. It aims to see which medicine works better and is safer for patients, including those whose cancer has spread to the brain.
For: Carcinoma, Non-Small-Cell LungBrazil · China · Croatia - Active not recruitingPHASE3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This study looks at a new drug, IDE196, for certain advanced cancers that have specific genetic changes called GNAQ/11 mutations or PRKC fusions. It checks if the drug is safe and effective alone or when combined with other existing cancer drugs.
For: Metastatic Uveal Melanoma · Cutaneous Melanoma · Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
This study looks at a drug called crizotinib for advanced lung cancer where specific gene changes (ROS1 or MET) are found. It aims to see how well the drug works in these patients.
For: Non-squamous Non-small-cell Lung Cancer · Stage IV Non-small Cell Lung Cancer · ROS1 Gene RearrangementCanada - Active not recruitingPHASE3
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
This study compares two drugs, lorlatinib and crizotinib, for people with a specific type of advanced lung cancer called ALK-positive NSCLC. It aims to see if lorlatinib works better at stopping the cancer from growing for longer. This is for patients who haven't had previous treatment for their advanced cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia